EXAS logoEXAS
Exact Sciences Corp.

11,218
Loading...
Loading...
News
all
press releases
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Zacks·2d ago
News Placeholder
More News
News Placeholder
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Zacks·22d ago
News Placeholder
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Zacks·24d ago
News Placeholder
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Zacks·25d ago
News Placeholder
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·26d ago
News Placeholder
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Zacks·29d ago
News Placeholder
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Zacks·29d ago
News Placeholder
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Zacks·1mo ago
News Placeholder
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago

Latest EXAS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.